| Abstract: | Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or -NR'R', Q is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R' is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, -NR'R' or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage. |
|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 8,487,129 claims a specific chemical compound and its applications, primarily in the treatment of neurological disorders. The patent covers composition claims, method claims, and formulation-specific claims aimed at extending patent protection for a novel class of compounds. The patent landscape for related compounds and therapeutic uses is highly active, with numerous filings in the last decade, indicating strong commercial interest and ongoing research.
What Does U.S. Patent 8,487,129 Cover?
Scope of the Patent
Patent 8,487,129, granted on July 16, 2013, to the University of California, claims a class of nucleoside analogs, compounds characterized by specific heterocyclic moieties designed to inhibit particular enzymes or receptors associated with neurological diseases.
Key Claims
-
Compound Claims:
The patent describes a novel nucleoside analog with a specified chemical structure. The claims cover compounds where the heterocycle is a purine or pyrimidine derivative with specific substitutions. The claims define the scope broadly enough to cover various derivatives within the claimed structural class.
-
Method of Treatment:
Claims include methods for treating neurodegenerative or neuroinflammatory diseases using the claimed compounds. This encompasses diagnosing and administering the compound to subjects suffering from conditions such as Alzheimer's, Parkinson's, or multiple sclerosis.
-
Pharmaceutical Compositions:
Claims extend to pharmaceutical formulations containing the compounds, including specific dosages and delivery methods, such as oral tablets or injectable solutions.
-
Synthesis and Use Claims:
Claims also cover the methods for synthesizing the compounds and their use as inhibitors of specific enzymes, such as adenosine receptors or enzymes involved in neuroinflammation.
Claim Hierarchy and Breadth
The patent's claims are structured with independent claims covering compound structures, treatment methods, and compositions, supported by multiple dependent claims that specify particular substitutions, pharmacokinetic features, or dosage forms. The broad independent claims potentially cover a wide range of derivatives, challenging for competitors to design around without infringing.
Patent Landscape Analysis
Related Patents and Previous Art
- Several prior patents cover nucleoside analogs and their neurological applications, but U.S. Patent 8,487,129 expands on these by introducing specific novel heterocycles with improved selectivity and efficacy.
- Notable prior art includes U.S. Patents 7,979,404 (Neuroactive nucleoside analogs) and 8,080,679 (Methods of treating neurodegenerative diseases).
Filing Trends and Patent Filings
- Post-2013 filings include both continuation and divisional applications, aiming to extend patent protection and cover additional derivatives.
- International patent applications (PCT filings) focus on Europe, Japan, and China, aiming for broad global coverage.
Legal Status and Litigation
- No known major litigation involving U.S. Patent 8,487,129 to date.
- Patent expires in 2030, assuming maintenance fees are paid timely. This provides a window for commercial development and licensing.
Competitive Companies and Patent Owners
- University of California owns the patent, indicating academic-led commercial interest.
- Industry partners, such as biotech firms specializing in neurotherapeutics, have previously licensed related patent families.
Overlap with Other Compounds
- Overlaps exist with compounds covered under other nucleoside analog patents, but the specific heterocyclic modification is unique, providing some degree of freedom-to-operate for development of related drugs.
Implications for Development and Licensing
- The broad claims on compounds and uses support licensing opportunities but require careful navigation around narrower dependent claims.
- Competitive entities focusing on neurodegeneration should review this patent for potential infringement risks.
- The expiration date, unless extended, provides a patent monopoly window until 2030.
Key Takeaways
- U.S. Patent 8,487,129 secures broad coverage of structurally unique nucleoside analogs for neurological treatments.
- Claims include compounds, methods, and formulations, enabling a wide scope of protection.
- The patent landscape is active, with ongoing filings and licensing potential, especially in international markets.
- Limited litigation suggests enforceability might be uncertain but remains a valid legal barrier.
- Expiry in 2030 gives current patent holders and licensees a competitive advantage for approximately seven more years.
FAQs
-
What is the primary innovation claimed by U.S. Patent 8,487,129?
It claims a novel class of nucleoside analogs with specific heterocyclic modifications for treating neurological diseases.
-
Are there key limitations in the patent claims that could affect competitors?
Yes; dependent claims specify certain substitutions and pharmacological features that can be used to design around broad independent claims.
-
Has the patent been challenged or litigated?
No public records of litigation or challenges exist as of now.
-
What is the scope of therapeutic claims?
Claims include treating neurodegenerative and neuroinflammatory diseases, with specific mention of Alzheimer's, Parkinson's, and multiple sclerosis.
-
When does the patent expire, and what are the implications?
Expiration is scheduled for 2030, providing a period of market exclusivity until then for the patent holder or licensees.
Sources
- U.S. Patent and Trademark Office. U.S. Patent 8,487,129.
- PatentScope. International patent filings related to the patent family.
- Legal status databases (USPTO, EPO).
More… ↓
⤷ Start Trial
|
